ROCKVILLE, Md., May 17, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical
stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company is scheduled to
host a conference call on Monday, May 23, 2016, at 8:30 a.m. (EDT) to
review IBS-C patient data from the first and second Phase 2 clinical trials for SYN-010. Synthetic Biologics previously reported
positive topline data from both Phase 2 clinical trials, including a reduction in breath methane levels, abdominal pain and
bloating, and an increase in the frequency of complete spontaneous bowel movements.
During the call, Dr. Mark Pimentel, Director of the GI Motility Program and Laboratory at
Cedars-Sinai, intends to recap the SYN-010 results to be included in the poster presentation at Digestive Disease Week® (DDW®
2016) on Sunday, May 22, 2016 in San Diego. The dial-in
information for the call is as follows:
U.S. toll free: 1-888-347-5280
International: +1 412-902-4280.
Participants are asked to dial in 15 minutes before the start of the call to register. The call and associated slide
presentation will be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/14387. An archive of the call will be available for approximately
six months at the same URL https://www.webcaster4.com/Webcast/Page/1096/14387 beginning approximately one hour after the call's
conclusion.
About SYN-010
SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by
certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause
of IBS-C. SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic
absorption, thereby targeting a major cause of IBS-C, not just the symptoms. To access the SYN-010 mechanism of action video on
Synthetic Biologics' website, please click
here.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome
while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development are: (1) SYN-010 which is
intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable
bowel syndrome with constipation (IBS-C), and (2) SYN-004 which is designed to protect the gut microbiome from the effects of
certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and
antibiotic-associated diarrhea (AAD). In collaboration with Intrexon Corporation, the Company is also developing preclinical
stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for
the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding
the potential benefits of SYN-004 and SYN-010. These forward-looking statements are based on management's expectations and
assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are
difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those
set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others, Synthetic Biologics' product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior results, Synthetic Biologics' ability to initiate clinical
trials and if initiated, to complete them on time and achieve desired results and benefits, Synthetic Biologics' clinical trials
continuing enrollment as expected, Synthetic Biologics' ability to obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics' ability to
promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics' products, Synthetic Biologics' ability to maintain its
license agreements, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and
remaining profitable, Synthetic Biologics' ability to establish and maintain collaborations, Synthetic Biologics' ability to
obtain or maintain the capital or grants necessary to fund its research and development activities, a loss of any of Synthetic
Biologics' key scientists or management personnel, and other factors described in Synthetic Biologics' Annual Report on
Form 10-K for the year ended December 31, 2015 and its other filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this
release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as required by law.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-host-post-ddw-2016-conference-call-to-recap-syn-010-phase-2-clinical-trial-results-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c-300269616.html
SOURCE Synthetic Biologics, Inc.